Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

India API Manufacturer To Invest $300 Million In Malaysia Operation

This article was originally published in PharmAsia News

Executive Summary

India-based Malladi Drugs and Pharmaceuticals, maker of active pharmaceutical ingredients, plans to set up a $300 million operation in Malaysia. According to Malaysian Biotechnology, a government agency promoting biotech, Malladi is being encouraged to locate in one of the country's biotech hubs. BioTech CEO Mizal Mahmood said the Malaysian branch would offer the entire range for contract manufacturing beginning with API formulation. Malladi plans eventually to expand into services for the contract research sector in Malaysia. (Click here for more

Table

View full table

Tags:
Latest Headlines

Erasca Revamps With Two In-Licensings, $160m Private Placement

Amgen’s Imdelltra Wins FDA Nod In Underserved SCLC Population

AstraZeneca Confident Of Cementing Lead In Respiratory

Pipeline Watch: Six Approvals And 12 Phase III Readouts

See All
UsernamePublicRestriction

Register

SC067091

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By